OSI sues Teva, Mylan for Tarceva patent infringement

Another day, another patent infringement lawsuit. Melville, NY-based OSI Pharmaceuticals says its suing Teva Pharmaceutical Industries and Mylan for trying to market generic versions of the daily cancer med Tarceva. Unless a court overturns the patent, OSI says the lawsuits will keep the FDA from approving Teva and Mylan's ANDAs until May 18, 2012. "OSI plans to vigorously protect and enforce the intellectual property rights of Tarceva," the company said in a statement.

Tarceva, a daily treatment for pancreatic and lung cancer, is marketed in the U.S. by OSI and Genentech.

- check out the OSI release

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.